HeartBeam (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target

Austin, Texas, United States, March 3rd, 2026, FinanceWire

New report upgrades HeartBeam to buy, raises 12-month price target to $4, citing regulatory progress and company’s transition toward commercialization.
Joseph Gunnar characterized the FDA clearance of HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment as a “critical regulatory milestone.”
The research report underscores the company’s targeted go-to-market strategy.

Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. A medical tech company, HeartBeam will introduce its FDA-cleared cable-free, synthesized 12-lead ECG system designed to deliver clinical-grade cardiac insights for arrhythmia assessment in a portable format, and the upgrade reflects growing confidence in the company’s commercial launch strategy and long-term opportunity.

“We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection,” the February 2026 report states. The report highlights a significant turning point for the company following FDA clearance of its 12-lead ECG synthesis…

Contact

IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com

Contact

From the newsroom

Costco Stock Has Fallen 20% Four Times in a Decade — Long-Term Holders Still Made a Fortune

EWZ Stock Just Had a One-in-58-Quadrillion Crash, Here’s What Actually Happened

Bank of England data show firms borrowing more as mortgage lending slows in September

Why Kazakhstan’s New Economic Strategy Matters Beyond Its Borders